Which has stronger earnings & valuation, SIBN or TMDX?

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.08 -$18.90M -$0.34 N/A TransMedics Group $605.49M 5.14 $190.29M $3.89 23.13

Does the media favor SIBN or TMDX?

In the previous week, TransMedics Group had 10 more articles in the media than SiBone. MarketBeat recorded 16 mentions for TransMedics Group and 6 mentions for SiBone. TransMedics Group's average media sentiment score of 1.16 beat SiBone's score of 0.50 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 12 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, SIBN or AXGN?

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.08 -$18.90M -$0.34 N/A AxoGen $225.21M 11.52 -$15.70M -$0.68 N/A

Is SIBN or AXGN more profitable?

SiBone has a net margin of -6.85% compared to AxoGen's net margin of -13.36%. SiBone's return on equity of -8.23% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% AxoGen -13.36% -8.90% -6.47%

Does the media refer more to SIBN or AXGN?

In the previous week, AxoGen had 3 more articles in the media than SiBone. MarketBeat recorded 9 mentions for AxoGen and 6 mentions for SiBone. AxoGen's average media sentiment score of 0.99 beat SiBone's score of 0.50 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SIBN or ATRC?

AtriCure has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.08 -$18.90M -$0.34 N/A AtriCure $569.62M 4.60 -$11.45M $0.21 245.33

Is SIBN or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to SiBone's net margin of -6.85%. AtriCure's return on equity of 2.34% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% AtriCure 1.85% 2.34% 1.77%

Does the media refer more to SIBN or ATRC?

In the previous week, AtriCure had 13 more articles in the media than SiBone. MarketBeat recorded 19 mentions for AtriCure and 6 mentions for SiBone. AtriCure's average media sentiment score of 0.84 beat SiBone's score of 0.50 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 9 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, BFLY or SIBN?

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Butterfly Network $97.61M 20.00 -$77.06M -$0.29 N/A SiBone $200.93M 4.08 -$18.90M -$0.34 N/A

Does the media prefer BFLY or SIBN?

In the previous week, Butterfly Network had 4 more articles in the media than SiBone. MarketBeat recorded 10 mentions for Butterfly Network and 6 mentions for SiBone. Butterfly Network's average media sentiment score of 0.79 beat SiBone's score of 0.50 indicating that Butterfly Network is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SIBN or ESTA more profitable?

SiBone has a net margin of -6.85% compared to Establishment Labs' net margin of -15.82%. SiBone's return on equity of -8.23% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% Establishment Labs -15.82% -196.69% -10.73%

Does the media refer more to SIBN or ESTA?

In the previous week, SiBone had 1 more articles in the media than Establishment Labs. MarketBeat recorded 6 mentions for SiBone and 5 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.05 beat SiBone's score of 0.50 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SiBone (SIBN) Competitors

$18.50 -0.14 (-0.75%)

As of 09/4/2026 04:00 PM Eastern

Compare

SIBN vs. TMDX, AXGN, ATRC, BFLY, and ESTA

Should you buy SiBone stock or one of its competitors? SiBone's main competitors and comparable companies include TransMedics Group (TMDX), AxoGen (AXGN), AtriCure (ATRC), Butterfly Network (BFLY), and Establishment Labs (ESTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does SiBone compare to TransMedics Group?

SiBone (NASDAQ:SIBN) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

98.1% of SiBone shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

SiBone has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

SiBone presently has a consensus price target of $24.17, indicating a potential upside of 30.63%. TransMedics Group has a consensus price target of $124.18, indicating a potential upside of 38.01%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

TransMedics Group has a net margin of 22.69% compared to SiBone's net margin of -6.85%. TransMedics Group's return on equity of 15.88% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
TransMedics Group	22.69%	15.88%	5.95%

In the previous week, TransMedics Group had 10 more articles in the media than SiBone. MarketBeat recorded 16 mentions for TransMedics Group and 6 mentions for SiBone. TransMedics Group's average media sentiment score of 1.16 beat SiBone's score of 0.50 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	12 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.08	-$18.90M	-$0.34	N/A
TransMedics Group	$605.49M	5.14	$190.29M	$3.89	23.13

Summary

TransMedics Group beats SiBone on 14 of the 15 factors compared between the two stocks.

How does SiBone compare to AxoGen?

SiBone (NASDAQ:SIBN) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

SiBone has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.08	-$18.90M	-$0.34	N/A
AxoGen	$225.21M	11.52	-$15.70M	-$0.68	N/A

In the previous week, AxoGen had 3 more articles in the media than SiBone. MarketBeat recorded 9 mentions for AxoGen and 6 mentions for SiBone. AxoGen's average media sentiment score of 0.99 beat SiBone's score of 0.50 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has a net margin of -6.85% compared to AxoGen's net margin of -13.36%. SiBone's return on equity of -8.23% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
AxoGen	-13.36%	-8.90%	-6.47%

SiBone currently has a consensus price target of $24.17, suggesting a potential upside of 30.63%. AxoGen has a consensus price target of $51.56, suggesting a potential upside of 6.78%. Given SiBone's higher possible upside, equities analysts plainly believe SiBone is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

98.1% of SiBone shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

SiBone and AxoGen tied by winning 8 of the 16 factors compared between the two stocks.

How does SiBone compare to AtriCure?

SiBone (NASDAQ:SIBN) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

98.1% of SiBone shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SiBone currently has a consensus target price of $24.17, suggesting a potential upside of 30.63%. AtriCure has a consensus target price of $52.00, suggesting a potential upside of 0.93%. Given SiBone's higher possible upside, equities analysts plainly believe SiBone is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

AtriCure has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.08	-$18.90M	-$0.34	N/A
AtriCure	$569.62M	4.60	-$11.45M	$0.21	245.33

SiBone has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

In the previous week, AtriCure had 13 more articles in the media than SiBone. MarketBeat recorded 19 mentions for AtriCure and 6 mentions for SiBone. AtriCure's average media sentiment score of 0.84 beat SiBone's score of 0.50 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	9 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure has a net margin of 1.85% compared to SiBone's net margin of -6.85%. AtriCure's return on equity of 2.34% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
AtriCure	1.85%	2.34%	1.77%

Summary

AtriCure beats SiBone on 15 of the 16 factors compared between the two stocks.

How does SiBone compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and SiBone (NASDAQ:SIBN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

SiBone has a net margin of -6.85% compared to Butterfly Network's net margin of -66.74%. SiBone's return on equity of -8.23% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
SiBone	-6.85%	-8.23%	-6.07%

37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 22.0% of Butterfly Network shares are held by insiders. Comparatively, 4.0% of SiBone shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	20.00	-$77.06M	-$0.29	N/A
SiBone	$200.93M	4.08	-$18.90M	-$0.34	N/A

Butterfly Network has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Butterfly Network currently has a consensus price target of $5.56, indicating a potential downside of 24.11%. SiBone has a consensus price target of $24.17, indicating a potential upside of 30.63%. Given SiBone's stronger consensus rating and higher possible upside, analysts clearly believe SiBone is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Butterfly Network had 4 more articles in the media than SiBone. MarketBeat recorded 10 mentions for Butterfly Network and 6 mentions for SiBone. Butterfly Network's average media sentiment score of 0.79 beat SiBone's score of 0.50 indicating that Butterfly Network is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SiBone beats Butterfly Network on 9 of the 16 factors compared between the two stocks.

How does SiBone compare to Establishment Labs?

SiBone (NASDAQ:SIBN) and Establishment Labs (NASDAQ:ESTA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

SiBone has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.08	-$18.90M	-$0.34	N/A
Establishment Labs	$211.08M	10.49	-$51.06M	-$1.31	N/A

SiBone has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

In the previous week, SiBone had 1 more articles in the media than Establishment Labs. MarketBeat recorded 6 mentions for SiBone and 5 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.05 beat SiBone's score of 0.50 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.1% of SiBone shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SiBone has a net margin of -6.85% compared to Establishment Labs' net margin of -15.82%. SiBone's return on equity of -8.23% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
Establishment Labs	-15.82%	-196.69%	-10.73%

SiBone currently has a consensus target price of $24.17, indicating a potential upside of 30.63%. Establishment Labs has a consensus target price of $100.25, indicating a potential upside of 34.94%. Given Establishment Labs' stronger consensus rating and higher probable upside, analysts clearly believe Establishment Labs is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

SiBone and Establishment Labs tied by winning 8 of the 16 factors compared between the two stocks.

Get SiBone News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIBN vs. The Competition

Export

Metric	SiBone	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$820.46M	$5.76B	$7.25B	$12.91B
Dividend Yield	N/A	1.76%	2.53%	9.14%
P/E Ratio	-54.41	25.94	274.10	25.45
Price / Sales	4.08	85.20	687.92	125.90
Price / Cash	N/A	32.98	77.08	52.44
Price / Book	4.50	6.06	12.85	6.17
Net Income	-$18.90M	$150.92M	$3.49B	$350.08M
7 Day Performance	-3.70%	-1.22%	1.04%	-0.14%
1 Month Performance	1.98%	2.18%	5.39%	0.94%
1 Year Performance	13.57%	9.95%	24.18%	14.02%

SiBone Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIBN SiBone	2.3488 of 5 stars	$18.50 -0.8%	$24.17 +30.6%	+13.6%	$820.46M	$200.93M	N/A	350	News Coverage Insider Trade
TMDX TransMedics Group	4.479 of 5 stars	$82.75 -2.5%	$124.18 +50.1%	-13.5%	$2.86B	$605.49M	21.27	210	News Coverage Positive News Gap Down
AXGN AxoGen	2.5662 of 5 stars	$50.09 -1.3%	$51.56 +2.9%	+202.1%	$2.69B	$225.21M	N/A	450	News Coverage Positive News Insider Trade
ATRC AtriCure	2.6598 of 5 stars	$48.76 +0.8%	$49.89 +2.3%	+45.6%	$2.48B	$534.53M	232.20	1,300	Analyst Forecast Insider Trade
BFLY Butterfly Network	1.3444 of 5 stars	$7.93 +0.5%	$5.56 -29.9%	+371.4%	$2.11B	$97.61M	N/A	460	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIBN) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SiBone (SIBN) Competitors

SIBN vs. TMDX, AXGN, ATRC, BFLY, and ESTA

How does SiBone compare to TransMedics Group?

Summary

How does SiBone compare to AxoGen?

Summary

How does SiBone compare to AtriCure?

Summary

How does SiBone compare to Butterfly Network?

Summary

How does SiBone compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SiBone (SIBN) Competitors

SIBN vs. TMDX, AXGN, ATRC, BFLY, and ESTA

How does SiBone compare to TransMedics Group?

Do insiders and institutionals believe in SIBN or TMDX?

Which has more risk and volatility, SIBN or TMDX?

Do analysts recommend SIBN or TMDX?

Is SIBN or TMDX more profitable?

Does the media favor SIBN or TMDX?

Which has stronger earnings & valuation, SIBN or TMDX?

Summary

How does SiBone compare to AxoGen?

Which has more risk and volatility, SIBN or AXGN?

Which has preferable earnings and valuation, SIBN or AXGN?

Does the media refer more to SIBN or AXGN?

Is SIBN or AXGN more profitable?

Do analysts prefer SIBN or AXGN?

Do insiders & institutionals hold more shares of SIBN or AXGN?

Summary

How does SiBone compare to AtriCure?

Do insiders and institutionals have more ownership in SIBN or ATRC?

Do analysts recommend SIBN or ATRC?

Which has preferable valuation & earnings, SIBN or ATRC?

Which has more risk and volatility, SIBN or ATRC?

Does the media refer more to SIBN or ATRC?

Is SIBN or ATRC more profitable?

Summary

How does SiBone compare to Butterfly Network?

Is BFLY or SIBN more profitable?

Do insiders & institutionals believe in BFLY or SIBN?

Which has better valuation and earnings, BFLY or SIBN?

Which has more risk and volatility, BFLY or SIBN?

Do analysts rate BFLY or SIBN?

Does the media prefer BFLY or SIBN?

Summary

How does SiBone compare to Establishment Labs?

Which has higher earnings and valuation, SIBN or ESTA?

Which has more volatility & risk, SIBN or ESTA?

Does the media refer more to SIBN or ESTA?

Do insiders and institutionals believe in SIBN or ESTA?

Is SIBN or ESTA more profitable?

Do analysts recommend SIBN or ESTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools